Search results for "medicine.drug_class"

showing 10 items of 2726 documents

Structure, Biosynthesis, and Bioactivity of Photoditritide from Photorhabdus temperata Meg1

2019

A new cyclic peptide photoditritide (1), containing two rare amino acid d-homoarginine residues, was isolated from Photorhabdus temperata Meg1 after the nonribosomal peptide synthetase encoding gene pdtS was activated via promoter exchange. The structure of 1 was elucidated by HR-MS and NMR experiments. The absolute configurations of amino acids were determined according to the advanced Marfey's method after hydrolysis of 1. Bioactivity testing of 1 revealed potent antimicrobial activity against Micrococcus luteus with an MIC value of 3.0 μM and weak antiprotozoal activity against Trypanosoma brucei rhodesiense with an IC50 value of 13 μM. Additionally, the biosynthetic pathway of 1 was als…

medicine.drug_classPharmaceutical Science01 natural sciencesAnalytical Chemistrychemistry.chemical_compoundHydrolysisBiosynthesisNonribosomal peptideDrug DiscoverymedicinePharmacologychemistry.chemical_classificationbiology010405 organic chemistryOrganic ChemistryTrypanosoma brucei rhodesiensebiology.organism_classificationCyclic peptide0104 chemical sciencesAmino acid010404 medicinal & biomolecular chemistryComplementary and alternative medicinechemistryBiochemistryAntiprotozoalMolecular MedicineMicrococcus luteusJournal of Natural Products
researchProduct

In Vivo Studies on the Anti-Inflammatory Activity of Pachymic and Dehydrotumulosic Acids

2000

Pachymic and dehydrotumulosic acids were studied in different models of acute and chronic inflammation. They proved to be active in most of the methods applied. None of them were active against arachidonic acid-induced ear edema. Dehydrotumulosic acid significantly diminished the mouse ear edema induced by ethyl phenylpropiolate, while pachymic acid was ineffective. When the putative corticoid-like mechanism of both compounds was explored, pachymic acid activity was partially abolished by the glucocorticoid receptor antagonist progesterone, but dehydrotumulosic acid activity was not affected. In vivo experiments demonstrated the inhibition by both principles of the phospholipase A2 (PLA2)-i…

medicine.drug_classPharmaceutical SciencePharmacologyAnti-inflammatoryAnalytical ChemistryMicechemistry.chemical_compoundPhospholipase A2In vivoDrug DiscoverymedicineAnimalsPharmacologybiologyAntiglucocorticoidAnti-Inflammatory Agents Non-SteroidalOrganic ChemistryFungiBiological activityTriterpenesExtravasationComplementary and alternative medicinechemistryBiochemistryMechanism of actionEnzyme inhibitorbiology.proteinMolecular MedicineFemalemedicine.symptomPlanta Medica
researchProduct

Repurposing of the ALK inhibitor crizotinib for acute leukemia and multiple myeloma cells

2021

Crizotinib was a first generation of ALK tyrosine kinase inhibitor approved for the treatment of ALK-positive non-small-cell lung carcinoma (NSCLC) patients. COMPARE and cluster analyses of transcriptomic data of the NCI cell line panel indicated that genes with different cellular functions regulated the sensitivity or resistance of cancer cells to crizotinib. Transcription factor binding motif analyses in gene promoters divulged two transcription factors possibly regulating the expression of these genes, i.e., RXRA and GATA1, which are important for leukemia and erythroid development, respectively. COMPARE analyses also implied that cell lines of various cancer types displayed varying degr…

medicine.drug_classPharmaceutical Scienceacute myeloid leukemiaArticletranscriptomicsPharmacy and materia medicaDrug Discoverytyrosine kinase inhibitorsmedicineCytotoxic T cellnetwork pharmacologyddc:610biologyCrizotinibdrug repurposingChemistryTopoisomeraseRMyeloid leukemiaCell cyclemedicine.diseaseALK inhibitorRS1-441multiple myelomaLeukemiaCancer cellbiology.proteinCancer researchMolecular MedicineMedicinemedicine.drug
researchProduct

Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs

2016

Tyrosine kinase inhibitors (TKIs), which have revolutionized cancer therapy over the past 15 years, are limited in their clinical application due to serious side effects. Therefore, we converted two approved TKIs (sunitinib and erlotinib) into 2-nitroimidazole-based hypoxia-activatable prodrugs. Kinetics studies showed very different stabilities over 24 h; however, fast reductive activation via E. coli nitroreductase could be confirmed for both panels. The anticancer activity and signaling inhibition of the compounds against various human cancer cell lines were evaluated in cell culture. These data, together with molecular docking simulations, revealed distinct differences in the impact of …

medicine.drug_classPharmacology010402 general chemistry01 natural sciencesBiochemistryArticleTyrosine-kinase inhibitor03 medical and health sciencesNitroreductase0302 clinical medicinetyrosine kinase inhibitorsDrug DiscoverymedicinecancerEpidermal growth factor receptorGeneral Pharmacology Toxicology and PharmaceuticsPharmacologybiologyhypoxiaSunitinibChemistryOrganic ChemistryProdrugtargeted therapeutic0104 chemical sciencesSettore CHIM/03 - Chimica Generale E InorganicaCell culture030220 oncology & carcinogenesisbiology.proteinMolecular MedicineErlotinibprodrugTyrosine kinasemedicine.drugChemMedChem
researchProduct

(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.

2015

Breast cancer remains the leading cause of cancer-related death among women. The invasive triple-negative subtype is unresponsive to estrogen therapy, and few effective treatments are available. In search of new chemical scaffolds to target this disease, we conducted a phenotypic screen against the human breast carcinoma cell lines MDA-MB-231, MA11, and MCF-7 using terrestrial natural products. Natural products that preferentially inhibited proliferation of triple-negative MDA-MB-231 cells over estrogen receptor-positive cells were further studied; herein we focused on the abietanes. The activity of the abietane carnosol prompted us to generate a focus library from the readily available (+)…

medicine.drug_classPhenotypic screeningApoptosisTriple Negative Breast NeoplasmsPharmacologyCarnosolchemistry.chemical_compoundStructure-Activity RelationshipBreast cancerCell Line TumorDrug DiscoverymedicineHumansTriple-negative breast cancerCell ProliferationPharmacologyBiological ProductsDose-Response Relationship DrugMolecular StructureCell growthDrug discoveryOrganic ChemistryStereoisomerismGeneral MedicineTriple Negative Breast Neoplasmsmedicine.diseaseAntineoplastic Agents PhytogenicchemistryEstrogenAbietanesMCF-7 CellsFemaleDrug Screening Assays AntitumorEuropean journal of medicinal chemistry
researchProduct

New hydrogel matrices containing an anti-inflammatory agent. Evaluation of in vitro release and photoprotective activity.

2002

In the present work. the preparation and characterization of hydrogels based on alpha,beta-polyaspartylhydrazide (PAHy) chemically crosslinked with ethyleneglycol diglycidylether (EGDGE) containing Tolmetin sodium salt, are reported. In particular, these samples have been prepared both as water swellable microparticles and as gels at two different crosslinking degrees. The incorporation of Tolmetin sodium salt in PAHy-EGDGE microparticles has been performed after the crosslinking reaction by a soaking procedure or during the formation of the network. The influence of drug loading procedure on Tolmetin release has been evaluated by performing in vitro release study in simulated gastrointesti…

medicine.drug_classPhotochemistrySodiumBiophysicsSynthetic membranechemistry.chemical_elementSalt (chemistry)BioengineeringIn Vitro TechniquesCrystallography X-RayAnti-inflammatoryHydrogel Polyethylene Glycol DimethacrylateBiomaterialsmedicineOrganic chemistryTolmetinchemistry.chemical_classificationChromatographyAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseIn vitroHemolysischemistryMechanics of MaterialsSelf-healing hydrogelsCeramics and CompositesTolmetinmedicine.drugBiomaterials
researchProduct

Kaempferol as a dietary anti-inflammatory agent: current therapeutic standing

2020

Inflammation is a physiological response to different pathological, cellular or vascular damages due to physical, chemical or mechanical trauma. It is characterized by pain, redness, heat and swelling. Current natural drugs are carefully chosen as a novel therapeutic strategy for the management of inflammatory diseases. Different phytochemical constituents are present in natural products. These phytochemicals have high efficacy both in vivo and in vitro. Among them, flavonoids occur in many foods, vegetables and herbal medicines and are considered as the most active constituent, having the ability to attenuate inflammation. Kaempferol is a polyphenol that is richly found in fruits, vegetabl…

medicine.drug_classPhytochemicalsAnti-Inflammatory AgentsPharmaceutical ScienceBiological AvailabilityReviewChemical FractionationAnti-inflammatoryAnalytical Chemistrylcsh:QD241-441therapeutic utility03 medical and health scienceschemistry.chemical_compoundStructure-Activity Relationship0302 clinical medicinelcsh:Organic chemistryDrug DiscoveryToxicity TestsmedicineAnimalsHumansPhysical and Theoretical ChemistryKaempferols030304 developmental biologyTherapeutic strategyFlavonoids0303 health sciencesBiological ProductskaempferolPlants MedicinalTraditional medicineOrganic Chemistryfood and beveragesKaempferol Anti-Inflammatory TherapyBioavailabilityReview articlechemistryPhytochemicalChemistry (miscellaneous)Polyphenolinflammation030220 oncology & carcinogenesisDietary SupplementsMolecular MedicineKaempferol
researchProduct

Demonstration of P29, an oestrogen receptor-associated tumor marker, in human term placenta.

1991

A Mr29,000 serine phosphoprotein (P29) related to oestradiol receptor was studied in human term placenta with the use of a specific monoclonal antibody (D5). D5 was used with two different methods, immunohistochemistry and immunoradiometry. For immunohistochemistry, an indirect immunoperoxidase method was chosen to detect P29 in methacarn-fixed, wax-embedded sections. P29 was mostly confined to the syncytiotrophoblast surrounding placental villi, staining being positive in both cytoplasm and nuclei. The stroma of villi was negative. Content of P29 was uniformly high in crude placental cytosol, as measured by immunoradiometry assays. Specificity of D5 against P29 in placenta was tested by an…

medicine.drug_classPlacentaBiologyMonoclonal antibodySyncytiotrophoblastPregnancyPlacentamedicineBiomarkers TumorSerineHumansHeat-Shock ProteinsImmunoperoxidaseObstetrics and GynecologyAntibodies MonoclonalPhosphoproteinsMolecular biologyImmunohistochemistryStainingTrophoblastsmedicine.anatomical_structureReproductive MedicineReceptors EstrogenCytoplasmPhosphoproteinembryonic structuresImmunohistochemistryFemaleImmunoradiometric AssayDevelopmental BiologyPlacenta
researchProduct

Immunonegative Staining: Epitope Localization on Macromolecules

1996

Relevant literature relating to immunonegative staining is reviewed and integrated with current research of the author and others. The immunonegative staining procedure has been utilized for the study of epitope localization on immune complexes formed from keyhole limpet hemocyanin type 2 (KLH2) di- and multidecamers, and the 20S and 26S proteasome from Xenopus laevis. The IgG linkage pattern of molecules in small immune complexes is considered to provide the most reliable indication of epitope location. For both KLH2 and the 20S proteasome, using domain-specific monoclonal antibodies and a 32-kDa (p32) subunit-specific polyclonal antibody, respectively, it is shown that epitopes (KLH2, sub…

medicine.drug_classProtein subunitXenopusBiologybiology.organism_classificationMonoclonal antibodyMolecular biologyGeneral Biochemistry Genetics and Molecular BiologyEpitopeProteasomePolyclonal antibodiesmedicinebiology.proteinBiophysicsMolecular BiologyKeyhole limpet hemocyaninMacromoleculeMethods
researchProduct

Treatment of pulmonary embolism.

2015

International audience; The treatment of pulmonary embolism is going to be deeply modified by the development of Direct Oral Anticoagulants (DOACs). There are currently three anti-Xa factors (rivaroxaban, apixaban, edoxaban) and one anti-IIa factor (dabigatran) labeled by the FDA and the EMA. All these drugs are direct anticoagulant, orally effective, without the need for adaptation to hemostasis test. As kidney excretion is involved for all of them, they are contra-indicated in patients with severe renal failure (creatinine clearance<30mL/min according to Cockcroft & Gault formula). All the anti-Xa factor drugs are metabolized by liver cytochromes and then contra-indicated in case of liver…

medicine.drug_classPyridinesPyridones[SDV]Life Sciences [q-bio]PopulationRenal functionRisk AssessmentAntithrombinsDabigatranchemistry.chemical_compoundRivaroxaban[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemEdoxaban[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyMedicineHumanseducationeducation.field_of_studyRivaroxabanClinical Trials as Topic[ SDV ] Life Sciences [q-bio]business.industryMedicine (all)AnticoagulantGeneral MedicineVenous Thromboembolism[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.disease3. Good healthPulmonary embolismDabigatranThiazolesAntithrombins; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Venous Thromboembolism; Medicine (all)chemistryAnesthesiaPyrazolesApixabanbusinessPulmonary Embolism[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drugFactor Xa Inhibitors
researchProduct